Latest & greatest articles for HIV Test

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on HIV Test or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on HIV Test and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for HIV Test

141. Home-based HIV voluntary counseling and testing in developing countries. (Abstract)

Home-based HIV voluntary counseling and testing in developing countries. The low uptake of HIV voluntary counseling and testing (VCT), an effective HIV prevention intervention, has hindered global attempts to prevent new HIV infections, as well as limiting the scale-up of HIV care and treatment for the estimated 38 million infected persons. According to UNAIDS, only 10% of HIV-infected individuals worldwide are aware of their HIV status. At this point in the HIV epidemic, a renewed focus has (...) shifted to prevention, and with it, a focus on methods to increase the uptake of HIV VCT. This review discusses home-based HIV VCT delivery models, which, given the low uptake of facility-based testing models, may be an effective avenue to get more patients on treatment and prevent new infections.(1) To identify and critically appraise studies addressing the implementation of home-based HIV voluntary counseling and testing in developing countries.(2) To determine whether home-based HIV voluntary

2007 Cochrane

142. Limitations of rapid HIV-1 tests during screening for trials in Uganda: diagnostic test accuracy study. Full Text available with Trip Pro

Limitations of rapid HIV-1 tests during screening for trials in Uganda: diagnostic test accuracy study. To evaluate the limitations of rapid tests for HIV-1.Diagnostic test accuracy study.Rural Rakai, Uganda.1517 males aged 15-49 screened for trials of circumcision for HIV prevention.Sensitivity, specificity, negative predictive values, and positive predictive values of an algorithm using three rapid tests for HIV, compared with the results of enzyme immunoassay and western blotting (...) as the optimal methods.Rapid test results were evaluated by enzyme immunoassay and western blotting. Sensitivity was 97.7%. Among 639 samples where the strength of positive bands was coded if the sample showed positivity for HIV, the algorithm had low specificity (94.1%) and a low positive predictive value (74.0%). Exclusion of 37 samples (5.8%) with a weak positive band improved the specificity (99.6%) and positive predictive value (97.7%).Weak positive bands on rapid tests for HIV should be confirmed

2007 BMJ

143. Universal antenatal human immunodeficiency virus (HIV) testing programme is cost-effective despite a low HIV prevalence in Hong Kong

Universal antenatal human immunodeficiency virus (HIV) testing programme is cost-effective despite a low HIV prevalence in Hong Kong Universal antenatal human immunodeficiency virus (HIV) testing programme is cost-effective despite a low HIV prevalence in Hong Kong Universal antenatal human immunodeficiency virus (HIV) testing programme is cost-effective despite a low HIV prevalence in Hong Kong Lee P M, Wong K H Record Status This is a critical abstract of an economic evaluation that meets (...) cost. The clinical estimates used in the model were not well reported and there is uncertainty in the results. Nevertheless, the authors' conclusions are broadly appropriate. Type of economic evaluation Cost-effectiveness analysis Study objective The study evaluated the cost-effectiveness of universal antenatal human immunodeficiency virus (HIV) testing in Hong Kong for women who attended antenatal clinics. Interventions A universal antenatal testing (UAT) programme over a period of 3 years and 4

2007 NHS Economic Evaluation Database.

144. Rapid point-of-care HIV testing in pregnant women: a systematic review and meta-analysis

Rapid point-of-care HIV testing in pregnant women: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

145. BRATS 03: Nucleic acids amplification tests (NAT) and other strategies for the detection of HIV-1 and HCV viruses in the selection of donated blood

BRATS 03: Nucleic acids amplification tests (NAT) and other strategies for the detection of HIV-1 and HCV viruses in the selection of donated blood BRATS 03: Nucleic acids amplification tests (NAT) and other strategies for the detection of HIV-1 and HCV viruses in the selection of donated blood BRATS 03: Nucleic acids amplification tests (NAT) and other strategies for the detection of HIV-1 and HCV viruses in the selection of donated blood Department of Science and Technology - Brazilian Health (...) Technology Assessment General Coordination (DECIT-CGATS) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Department of Science and Technology - Brazilian Health Technology Assessment General Coordination (DECIT-CGATS). BRATS 03: Nucleic acids amplification tests (NAT) and other strategies for the detection of HIV-1 and HCV viruses in the selection

2007 Health Technology Assessment (HTA) Database.

146. Rapid antibody testing for HIV

Rapid antibody testing for HIV Rapid antibody testing for HIV Rapid antibody testing for HIV HAYES, Inc. Citation HAYES, Inc.. Rapid antibody testing for HIV. Lansdale: HAYES, Inc.. Directory Publication. 2007 Authors' objectives

Rapid human immunodeficiency virus (HIV) antibody testing offers the potential to increase the number of people undergoing HIV testing and to provide faster results than HIV antibody tests that use enzyme immunoassays (EIAs) or enzyme-linked immunosorbent assay (...) (ELISA) methodology. The goal of rapid HIV testing is to improve access to testing, with the objective of reducing the prevalence of unrecognized infections, which is essential for appropriate and timely treatment and as part of an overall disease control strategy.

Timeliness warning This report has been archived and may contain outdated information. To request a copy of the report please contact the organisation directly. Project page URL Indexing Status Subject indexing assigned by CRD MeSH HIV

2007 Health Technology Assessment (HTA) Database.

147. OraSure HIV Point of care testing

OraSure HIV Point of care testing Horizon Scanning Technology Prioritising Summary OraSure HIV point-of-care testing August 2007 © Commonwealth of Australia 2007 ISBN Publications Approval Number: This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use or use within your organisation. Apart from any use as permitted under the Copyright Act 1968, all other rights are reserved (...) . OraSure HIV point-of-care testing: August 2007 1 PRIORITISING SUMMARY REGISTER ID: 000325 NAME OF TECHNOLOGY: ORASURE HIV POINT OF CARE TESTING PURPOSE AND TARGET GROUP: POINT OF CARE HIV TESTS ALLOW RAPID REPORTING OF RESULTS TO PATIENTS IN SETTINGS SUCH AS CLINICS. STAGE OF DEVELOPMENT (IN AUSTRALIA): : Yet to emerge ? Established ? Experimental ? Established but changed indication or modification of technique ? Investigational ? Should be taken out of use ? Nearly established AUSTRALIAN THERAPEUTIC

2007 Australia and New Zealand Horizon Scanning Network

148. Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure Full Text available with Trip Pro

Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure Sendi P, Gunthard HF, Simcock M, Ledergerber B, Schupbach J, Battegay M Record Status This is a critical abstract of an economic evaluation that meets (...) concluded that GART was cost-effective and beneficial to society. The methodology seems to have been appropriate, with some minor limitations, and was clearly and transparently reported. The conclusions reached by the authors appear to be appropriate. Type of economic evaluation Cost-effectiveness analysis Study objective The aim was to evaluate the clinical effect, cost and cost-effectiveness of human immunodeficiency virus (HIV) treatment optimisation using genotypic antiretroviral resistance testing

2007 NHS Economic Evaluation Database.

149. Rapid HIV testing at home: does it solve a problem or create one? (Abstract)

Rapid HIV testing at home: does it solve a problem or create one? The U.S. Food and Drug Administration (FDA) is considering approval of an over-the-counter, rapid HIV test for home use. To date, testimony presented before the FDA has been overwhelmingly supportive. Advocates have argued enthusiastically that there is value in empowering individuals to manage their HIV risks and have suggested that the availability of a rapid home HIV test will dramatically increase rates of disease detection (...) in communities that have proven difficult to reach and to link to appropriate care. The authors offer a more cautious perspective. According to what is already known about the market demand for over-the-counter HIV testing kits, their costs, and the performance of rapid HIV tests in that market, the authors do not anticipate that the rapid home test will have a profound impact either on the HIV public health crisis or on the populations in greatest need. Home HIV testing will attract a predominantly affluent

2006 Annals of Internal Medicine

150. Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites

Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites Kim S Y, Billah K, Lieu T A, Weinstein M C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined four strategies for vaccinating against hepatitis B virus (HBV) in potentially high-risk adults attending freestanding human immunodeficiency virus (HIV) counselling and testing sites (CTSs) or sexually transmitted disease (STD) clinics. The strategies were: routine vaccination without screening for prior immunity or infection (routine vaccination); screening for antibody

2006 NHS Economic Evaluation Database.

151. A meta-analysis of the effectiveness of alternative HIV counseling and testing methods to increase knowledge of HIV status Full Text available with Trip Pro

A meta-analysis of the effectiveness of alternative HIV counseling and testing methods to increase knowledge of HIV status A meta-analysis of the effectiveness of alternative HIV counseling and testing methods to increase knowledge of HIV status A meta-analysis of the effectiveness of alternative HIV counseling and testing methods to increase knowledge of HIV status Hutchinson A B, Branson B M, Kim A, Farnham P G CRD summary The authors concluded that there is strong evidence that rapid testing (...) considerably increases the proportion of patients who receive their human immunodeficiency virus test results. These conclusions appear to be supported by the data presented. However, details of review methods and a validity assessment were not reported, which makes it difficult to assess the reliability of the evidence. Authors' objectives To evaluate the effects of alternatives to conventional human immunodeficiency virus (HIV) counselling and testing (CT) on the receipt of HIV test results. Searching

2006 DARE.

152. Modelling the cost effectiveness of rapid point of care diagnostic tests for the control of HIV and other sexually transmitted infections among female sex workers Full Text available with Trip Pro

Modelling the cost effectiveness of rapid point of care diagnostic tests for the control of HIV and other sexually transmitted infections among female sex workers Modelling the cost effectiveness of rapid point of care diagnostic tests for the control of HIV and other sexually transmitted infections among female sex workers Modelling the cost effectiveness of rapid point of care diagnostic tests for the control of HIV and other sexually transmitted infections among female sex workers Vickerman (...) in the study population. Initially, the model was used to fit available data on HIV, Ng/Ct and genital ulcer disease (GUD) prevalence. Once this was achieved, the model was used to estimate the impact of SIDA2 improving diagnoses and then SIDA2 improving treatment, following which the authors explored how the treatment aspect would change if POC testing had been used. SIDA2 was an existing STI/HIV prevention project targeted at FSWs in the study setting. Outcomes assessed in the review The authors

2006 NHS Economic Evaluation Database.

153. Detection of acute infections during HIV testing in North Carolina. (Abstract)

Detection of acute infections during HIV testing in North Carolina. North Carolina has added nucleic acid amplification testing for the human immunodeficiency virus (HIV) to standard HIV antibody tests to detect persons with acute HIV infection who are viremic but antibody-negative.To determine the effect of nucleic acid amplification testing on the yield and accuracy of HIV detection in public health practice, we conducted a 12-month observational study of methods for state-funded HIV testing (...) . We compared the diagnostic performance of standard HIV antibody tests (i.e., enzyme immunoassay and Western blot analysis) with an algorithm whereby serum samples that yielded negative results on standard antibody tests were tested again with the use of nucleic acid amplification. A surveillance algorithm with repeated sensitive-less-sensitive enzyme immunoassay tests was also evaluated. HIV infection was defined as a confirmed positive result on a nucleic acid amplification test or as HIV

2005 NEJM

154. Diagnostic, monitoring, and resistance tests for HIV.

Diagnostic, monitoring, and resistance tests for HIV. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding for the National Guideline

2005 New York State Department of Health

155. Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. Full Text available with Trip Pro

Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. Recent cervical cancer screening guidelines state that the interval between screenings can be safely extended to 3 years in healthy women 30 years or older who have normal cytology results and have negative test results for oncogenic human papillomavirus (HPV) DNA.To determine the incidence of squamous intraepithelial lesions (SILs) in HIV-seropositive (...) than 500/microL (hazard ratio [HR], 1.2; 95% CI, 0.5-3.0), but not those with CD4 counts less than or equal to 500/microL (HR, 2.9; 95% CI, 1.2-7.1), was similar to that in HIV-seronegative women.The similar low cumulative incidence of any SIL among HIV-seronegative and HIV-seropositive women with CD4 counts greater than 500/microL and who had normal cervical cytology and HPV-negative test results suggests that similar cervical cancer screening practices may be applicable to both groups, although

2005 JAMA

156. HIV testing and diagnosis in infants and children.

HIV testing and diagnosis in infants and children. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding for the National Guideline

2005 New York State Department of Health

157. Cost-effectiveness of models for prevention of vertical HIV transmission: voluntary counseling and testing and choices of drug regimen

Cost-effectiveness of models for prevention of vertical HIV transmission: voluntary counseling and testing and choices of drug regimen Cost-effectiveness of models for prevention of vertical HIV transmission: voluntary counseling and testing and choices of drug regimen Cost-effectiveness of models for prevention of vertical HIV transmission: voluntary counseling and testing and choices of drug regimen Teerawattananon Y, Vos T, Tangcharoensathien V, Mugford M Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The present study compared four antiretroviral therapy (ART) regimens given in addition to voluntary counselling and testing (VCT) for preventing mother-to-child transmission of the human immunodeficiency virus (HIV

2005 NHS Economic Evaluation Database.

158. Genotypic resistance testing of antiretrovirals in HIV

Genotypic resistance testing of antiretrovirals in HIV Genotypic resistance testing of antiretrovirals in HIV Genotypic resistance testing of antiretrovirals in HIV Medical Services Advisory Committee Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Medical Services Advisory Committee. Genotypic resistance testing of antiretrovirals in HIV (...) . Canberra: Medical Services Advisory Committee (MSAC). MSAC application 1067. 2005 Authors' objectives This assessment was undertaken to provide the broadest possible advice regarding the safety, effectiveness and cost-effectiveness of genotypic resistance testing for antiretrovirals in patients infected with human immunodeficiency virus (HIV). Authors' conclusions MSAC found that genotypic resistance testing of antiretrovirals in HIV appeared to be safe and leads to changes in clinical management

2005 Health Technology Assessment (HTA) Database.

159. The cost-effectiveness of expanded testing for primary HIV infection Full Text available with Trip Pro

The cost-effectiveness of expanded testing for primary HIV infection The cost-effectiveness of expanded testing for primary HIV infection The cost-effectiveness of expanded testing for primary HIV infection Coco A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) and the conclusions drawn. Health technology Three diagnostic tests for primary human immunodeficiency virus (HIV) infection were examined: HIV-1 RNA assay (by polymerase chain reaction, branched-chain DNA, or transcription-mediated amplification); p24 antigen enzyme immunosorbent assay (EIA); and third-generation HIV-1 EIA. Type of intervention Diagnosis. Economic study type Cost-effectiveness analysis and cost-utility analysis. Study population The study population comprised a hypothetical cohort of patients

2005 NHS Economic Evaluation Database.

160. Should resistance testing be performed for treatment-naive HIV-infected patients: a cost-effectiveness analysis Full Text available with Trip Pro

Should resistance testing be performed for treatment-naive HIV-infected patients: a cost-effectiveness analysis Should resistance testing be performed for treatment-naive HIV-infected patients: a cost-effectiveness analysis Should resistance testing be performed for treatment-naive HIV-infected patients: a cost-effectiveness analysis Sax P E, Islam R, Walensky R P, Losina E, Weinstein M C, Goldie S J, Sadownik S N, Freedberg K A Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The authors studied whether genotype resistance testing should be performed for treatment-naive patients infected with the human immunodeficiency virus (HIV). Resistance testing took the form of a blood test and was compared with no resistance

2005 NHS Economic Evaluation Database.